

on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on April 15, 2026, ANI Pharmaceuticals Inc., 70 Lake Drive, East Windsor, New Jersey 08520, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Levorphanol	9220	II

The company plans to bulk manufacture the listed controlled substance for development and eventual use in a commercial drug product. No other activity for this drug code is authorized for this registration.

Thomas Prevoznik,
Deputy Assistant Administrator.
[FR Doc. 2026-08586 Filed 5-1-26; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[Docket No. DEA-1709]

Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.

SUMMARY: Patheon Pharmaceuticals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on March 18, 2026, Patheon Pharmaceuticals Inc., 2110 East Galbraith Road, Cincinnati, Ohio 45237-1625, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I

The company plans to bulk manufacture the listed controlled substance as an Active Pharmaceutical Ingredient that will be further synthesized into Food and Drug Administration approved dosage forms. No other activity for this drug code authorized for this registration.

Thomas Prevoznik,
Deputy Assistant Administrator.
[FR Doc. 2026-08585 Filed 5-1-26; 8:45 am]
BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Resource Conservation and Recovery Act

On April 28, 2026, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Southern District of Ohio

in the lawsuit entitled *United States et al. v. AK Steel Corp.*, Civil Action No. 1:00-cv-00530-JPH.

In 2001, the United States brought an action against Defendant AK Steel Corporation, now named Cleveland-Cliffs Steel Corporation, seeking among other things Defendant's performance of corrective actions under Section 3008(h) of the Resource Conservation Recovery Act ("RCRA"), 42 U.S.C. 6928(h), to address releases of hazardous waste at Defendant's Middletown Works steel production facility in Middletown, Ohio. On May 15, 2006, the Court entered a Consent Decree in Partial Resolution of Pending Claims (the "2006 Consent Decree") which resolved all claims brought by plaintiffs except for the United States' (and intervening plaintiffs') claims for corrective action under RCRA Section 3008(h). The 2006 Consent Decree required Defendant to perform various corrective action investigations under Section 3008(h) of RCRA, but the Parties agreed to defer resolution of the alleged liability of Defendant under Section 3008(h) of RCRA and to defer entering into an agreement governing implementation of such corrective measures until completion of the investigations. The Consent Decree lodged today establishes requirements for Defendant to complete corrective actions at seven areas in and around the Facility, which Defendant has been developing with EPA oversight pursuant to the 2006 CD. The Consent Decree thus resolves the last pending claim in this case.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Principal Deputy Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States et al. v. AK Steel Corp.*, D.J. Ref. No. 90-5-2-1-2189/4. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@usdoj.gov
By mail	Principal Deputy Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Any comments submitted in writing may be filed by the United States in whole or in part on the public court docket without notice to the commenter.